Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 8, 2014, Pages 1266-1273

  Ruggeri, M ^a   Tosetto, A ^a   Palandri, F ^b   Polverelli, N ^b   Mazzucconi, M G ^c   Santoro, C ^c   Gaidano, G ^d   Lunghi, M ^d   Zaja, F ^e   De Stefano, V ^f   Sartori, R ^g   Fazi, P ^h   Rodeghiero, F ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Azienda Ospedaliero Universitaria Maggiore della Carità   (Italy)

^e UNIVERSITY HOSPITAL OF UDINE   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g Castelfranco Veneto Hospital   (Italy)

^h GIMEMA Data Center   (Italy)

Author keywords

Epidemiology; Immune thrombocytopenic purpura; Splenectomy; Thrombosis; TMP mimetic peptide

Indexed keywords

HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CHILD; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VEIN THROMBOSIS; VERY ELDERLY; COMPLICATION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; THROMBOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; YOUNG ADULT;

EID: 84905640537     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12636     Document Type: Article

References (40)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-93.
2. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94: 909-13.
3. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR, Northern Region Haematology G. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122: 966-74.
4. Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, Fryzek J, Kaye JA. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009; 145: 235-44.
5. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-54.
6. Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95: 1167-75.
7. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AO, Norgaard M, Zhao S, Sorensen HT. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011; 152: 360-2.
8. Norgaard M, Severinsen MT, Lund Maegbaek M, Jensen AO, Cha S, Sorensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2012; 159: 109-11.
9. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379: 244-9.
10. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119: 334-45.
11. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010; 47: 2170-5.
12. Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 2010; 148: 638-45.
13. Comellas-Kirkerup L, Hernandez-Molina G, Cabral AR. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study. Blood 2010; 116: 3058-63.
14. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-34.
15. Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50: 172-5, 7.
16. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J, Group ITPS. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76: 205-13.
17. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004; 104: 956-60.
18. Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, Barbui T, Tura S, Baccaranion M, Gruppo Italiano per lo Studio delle Malattie Ematologiche dA. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005; 90: 72-7.
19. Stasi R, Stipa E, Masi M, Cecconi M, Scimo MT, Oliva F, Sciarra A, Perrotti AP, Adomo G, Amadori S, Papa G. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-42.
20. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-60.
21. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692-9.
22. National register of coronary and cerebrovascular events, Istituto Superiore di Sanitá, Roma. http//www.cuore.iss.it/eng/indicators/register.asp. Accessed 12 November 2013.
23. Shen LZ. Sample size determination for controlling the upper confidence limit of incidence rate of a binomial endpoint. J Biopharm Stat 1998; 8: 489-96.
24. StataCorp. Stata Statistical Software: Release 11.0. College Station, TX: Stata Corporation, 2010.
25. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2011.
26. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrere F, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371: 395-403.
27. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.
28. Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol 2013; 91: 423-36.
29. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A, Group ES. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121: 537-45.
30. Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013; 161: 411-23.
31. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.
32. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, Prins MH, Girolami A. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-41.
33. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009; 114: 2861-8.
34. Rodeghiero F, Ruggeri M. Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications? Br J Haematol 2012; 158: 16-29.
35. Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, Sorensen HT. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: a 10-year nationwide cohort study. J Thromb Haemost 2010; 8: 1413-6.
36. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013; 121: 4782-90.
37. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalcaci M, Inanc M. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760-4.
38. Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, Gouault M, Intrator L, Bierling P, Godeau B. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 2008; 142: 638-43.
39. Funauchi M, Hamada K, Enomoto H, Ikoma S, Ohno M, Kinoshita K, Horiuchi A. Characteristics of the clinical findings in patients with idiopathic thrombocytopenic purpura who are positive for anti-phospholipid antibodies. Intern Med 1997; 36: 882-5.
40. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, Olivieri M, Zaccari G, Gandolfo GM, Galli M. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84: 4203-8.